Cancer Vaccine Eliminates Tumors in Early Breast Cancer
Four injections of a new cancer vaccine resulted in the elimination of tumors in nearly 20% of women with a form of early breast cancer called ductal carcinoma in situ (DCIS). Discovery of the cancer vaccine may also help researchers apply their findings to invasive breast cancer and other certain solid tumors.
Cancer vaccine may fight early breast cancer
Ductal carcinoma in situ (DCIS) is the most common type of non-invasive breast cancer. This form of breast cancer originates in the milk ducts and has not spread beyond that point into normal surrounding breast tissue.
The American Cancer Society reports that about 63,300 new cases of DCIS will be diagnosed this year in the United States, which represents about 20% of new breast cancer cases. Having DCIS increases the risk of developing invasive breast cancer in the future or for having breast cancer come back. The majority of cancer recurrences happen within 5 to 10 years after the initial diagnosis.
The new cancer vaccine findings
A research team at the Perelman School of Medicine and the Abramson Cancer Center at the University of Pennsylvania have found that injecting 27 women who had HER2-positive DCIS with an anti-HER2 dendritic cell vaccine composed partly from each patient’s own cells was capable of eliminating the tumor in nearly 20% of the patients.
HER2-positive breast cancer is a breast cancer that tests positive for human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells. In about 20% of breast cancers, the cancer cells produce an excessive amount of HER2 due to a gene mutation.
The researchers also found that more than 85% of the women seemed to have a sustained immune response after receiving the vaccine series, which may reduce their risk of developing invasive breast cancer down the road.